Feasibility of postoperative adjuvant chemotherapy using carboplatin plus S-1 in completely resected non-small cell lung cancer patients. (18th August 2019)

• Record Type: Journal Article
• Authors: Inoue, Masayoshi; Kusumoto, Hidenori; Shiono, Hiroyuki; Shintani, Yasushi; Ose, Naoko; Sakamaki, Yasushi; Okami, Jiro; Higashiyama, Masahiko; Takeuchi, Yukiyasu
• Is Part Of: Journal of chemotherapy. Volume 31:Number 6(2019)
• Page Start: 343
• Page End: 348
• Publication Date: 2019-08-18
• Subjects: Lung cancer -- adjuvant chemotherapy -- carboplatin -- S-1 -- feasibility -- phase 2; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; 615.58
• DOI: 10.1080/1120009X.2019.1651002
• Languages: English
• ISSNs: 1120-009X

Abstract

Abstract : Feasibility is one of the major concerns during adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. A phase II clinical trial of adjuvant chemotherapy with four courses of carboplatin (AUC 5 at day 1) and S-1 (80 mg/m 2 /day for 2 weeks followed by a 2-week rest) was performed to evaluate the feasibility (UMIN 9101). The primary endpoint was the completion rate and the secondary endpoints were adverse events, 2-year overall survival and disease-free rates. Thirty-five non-small cell lung cancer patients were enrolled. The adjuvant chemotherapy completion rate was 85.3% (29/34); 17/34 (50%) patients completed 4 courses without dose reduction. There were no treatment-related deaths, and Grade 3/4 adverse events included neutropenia (38.2%), leukocytopenia (14.7%), anemia (20.6%), thrombocytopenia (20.6%), anorexia (5.9%), fatigue (5.9%), and oral mucositis (2.9%). Two-year overall and disease-free survival rates were 96.3% and 53.3%, respectively. Adjuvant chemotherapy with carboplatin plus S-1 is safe and feasible.